-
21.发明公开
公开(公告)号：EP4269586A1
公开(公告)日：2023-11-01
申请号：EP22170992.6
申请日：2022-04-29
IPC分类号： C12N15/113 , A61P9/12 , A61P9/04
摘要： The invention pertains to a compounds or compositions comprising antagonists of miR-92 which are useful in a method of treatment of a heart disease associated with or caused by a reduced ventricular elasticity and/or a diastolic dysfunction in a subject, which preferably is a subject suffering from Heart Failure with preserved Ejection Fraction (HFpEF). The invention provides such compounds and/or compositions, which are preferably nucleic acid based antagonists of miR-92, preferably oligonucleotide inhibitors, as well as uses and method for treating subjects.
-
公开(公告)号：EP4108231A1
公开(公告)日：2022-12-28
申请号：EP21181716.8
申请日：2021-06-25
发明人： Windbergs, Maike , Walther, Marcel , Rohde, Felix
IPC分类号： A61K9/00
摘要： The present invention relates to drug-containing polymer fibers or drug-containing fiber mats for ophthalmic use that are produced by electrospinning solutions of biocompatible polymers, and respective uses thereof.
-
23.发明公开
公开(公告)号：EP4058566A1
公开(公告)日：2022-09-21
申请号：EP20803200.3
申请日：2020-11-12
发明人： BODE, Helge , BOZHÜYÜK, Kenan , WATZEL, Jonas
IPC分类号： C12N9/00
-
公开(公告)号：EP4017981A1
公开(公告)日：2022-06-29
申请号：EP20789084.9
申请日：2020-10-08
申请人： Johann Wolfgang Goethe-Universität Frankfurt am Main , Rosalind Franklin University of Medicine and Science
发明人： HARTH, Simon , OREB, Mislav , CHOE, Jun-Yong
-
公开(公告)号：EP4013468A1
公开(公告)日：2022-06-22
申请号：EP20760786.2
申请日：2020-08-17
-
公开(公告)号：EP3463470A1
公开(公告)日：2019-04-10
申请号：EP17726276.3
申请日：2017-05-24
发明人： FLEMING, Ingrid , FRÖMEL, Timo , HU, Jiong , POPP, Rüdiger
IPC分类号： A61K45/06 , A61K31/17 , A61K31/4468 , A61P27/02
-
公开(公告)号：EP3262422A2
公开(公告)日：2018-01-03
申请号：EP16706602.6
申请日：2016-02-25
申请人： DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH , Johann Wolfgang Goethe-Universität Frankfurt am Main
摘要： The present invention provides a cellular system for the detection of the presence of one or more antibody species in sample, preferably a serum or plasma sample. The method is in particular useful for the analysis of patients who have been sensitized against blood group antigens expressed on erythrocytes, platelets or granulocytes. The system uses fluorescence labeled cells specific for each antigen and hence, for each antibody species. Provided are the methods, system and diagnostic kits for performing the methods of the invention. In addition, the present invention discloses a method for removing antibodies from a sample such as a serum sample. Such a method is useful for absorbing antibodies from poly-agglutinating sera.
-
公开(公告)号：EP3253872A1
公开(公告)日：2017-12-13
申请号：EP16703488.3
申请日：2016-02-03
IPC分类号： C12N15/113 , A61K31/7088 , A61K31/712 , A61P9/00 , A61P35/00
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/713 , C12N2310/11 , C12N2310/113 , C12N2310/14 , C12N2310/341
摘要： The present invention associates multiple long non-coding RNA (lncRNA) with key functions of endothelial cells. The lncRNA of the present invention are therefore useful as novel drug targets for the manufacturing of medicines for the treatment of cardiovascular diseases or pathological angiogenesis in context of proliferative diseases such as cancer. Modulation of the function or expression of the lncRNA of invention can induce or repress angiogenesis and vessel growth or repair in endothelial cells. Provided are further methods for the modulation of endothelial cell functions in vitro, for example, in the context of tissue engineering.
-
29.发明公开
公开(公告)号：EP3233729A2
公开(公告)日：2017-10-25
申请号：EP15841039.9
申请日：2015-12-08
IPC分类号： C01B33/107
CPC分类号： C01B33/107 , C07F7/0896 , C07F7/21
摘要： The invention relates to a method for producing perhalogenated hexasilane anion by reaction of halogenated monosilane in the presence of organo-substituted ammonium halide and/or organo-substituted phosphonium halide at temperatures in a range of 100 to 120°C, without using solvent, and to method for producing a cyclic silane compound of the formula Si
6 R
12 by reaction of [X]
2 [Si
6 Cl
14 ] with ALR
3 in at least one organic solvent, with R being chlorine or methyl and X being the same or different and a counter-cation and being preferably selected from organo-substituted ammonium, organo-substituted phosphonium, alkali metal ions and [(PEDETA)(H
2 SiCl)]
+ .摘要翻译： 本发明涉及在不使用溶剂的情况下，在有机取代的卤化铵和/或有机取代的卤化鏻存在下，在100-120℃的温度下，通过卤化甲硅烷的反应生产全卤代六硅烷阴离子的方法，以及 通过[X] 2 [Si 6 Cl 14]与ALR 3在至少一种有机溶剂中反应制备式Si 6 R 12的环状硅烷化合物的方法，其中R为氯或甲基且X为相同或不同的并且 反阳离子并且优选选自有机取代的铵，有机取代的鏻，碱金属离子和[（PEDETA）（H 2 SiCl）] +。
-
公开(公告)号：EP3081938A1
公开(公告)日：2016-10-19
申请号：EP15164834.2
申请日：2015-04-23
IPC分类号： G01N33/574 , G01N33/92
CPC分类号： G01N33/57438 , G01N33/92 , G01N2405/08 , G01N2800/7028
摘要： The present invention pertains to novel diagnostic procedures for the prognosis, diagnosis and monitoring of liver diseases such as hepatocellular carcinoma (HCC). The present invention provides sphingolipids and especially long chain ceramides as significant and highly prognostic serum biomarkers in HCC compared to liver cirrhosis. Therefore the invention in particular provides a method for detecting the presence or absence of a HCC in a liver cirrhosis patient using the disclosed biomarkers. Also provided is a method for monitoring the treatment success of a HCC treatment by monitoring the disclosed serum biomarkers. Finally the invention pertains to diagnostic kits for performing the disclosed methods of the invention.
摘要翻译： 本发明涉及用于预测，诊断和监测诸如肝细胞癌（HCC）的肝脏疾病的新型诊断程序。 与肝硬化相比，本发明提供了鞘脂类，特别是长链神经酰胺作为HCC中显着且高度预后的血清生物标志物。 因此，本发明特别提供了使用所公开的生物标志物检测肝硬化患者中HCC存在或不存在的方法。 还提供了通过监测所公开的血清生物标志物来监测HCC治疗的治疗成功的方法。 最后，本发明涉及用于执行本发明的公开方法的诊断试剂盒。
-
-
-
-
-
-
-
-
-
搜索结果
111 条记录 (耗时 0.023 秒)
